--- title: "Pre-market hot trades in US stocks: Akanda down 13.11% pre-market; DNA X down 12.66% pre-market" type: "News" locale: "en" url: "https://longbridge.com/en/news/289781829.md" description: "Akanda pre-market down 13.11%; DNA X pre-market down 12.66%; The LGL Group, Inc. pre-market up 218.18%; Freecast pre-market up 205.15%; Paranovus ENT Tech pre-market up 172.69%" datetime: "2026-06-15T12:17:05.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/289781829.md) - [en](https://longbridge.com/en/news/289781829.md) - [zh-HK](https://longbridge.com/zh-HK/news/289781829.md) --- # Pre-market hot trades in US stocks: Akanda down 13.11% pre-market; DNA X down 12.66% pre-market **Pre-market Hot Trades in US Stocks** Akanda is down 13.11% in pre-market trading. Based on recent key news: 1. On June 12, Akanda announced that it has regained compliance with Nasdaq listing requirements. The company submitted its delayed annual report for fiscal year 2025 on June 9, and Nasdaq notified it on June 10 that it had met the listing rules. This news may not have boosted market confidence, leading to a decline in stock price. 2. On June 12, Akanda canceled its special shareholder meeting due to failure to meet the conditions for convening the meeting. Concerns about the company's governance may have intensified, further affecting stock price performance. 3. On June 12, Akanda's stock has fallen over 75% in the past 12 months, underperforming the S&P 500 index. Long-term weakness in stock price may lead to insufficient investor confidence, impacting recent stock prices. The market has doubts about Akanda's governance and compliance. DNA X is down 12.66% in pre-market trading, with no significant news recently. Trading is active, and capital flows are evident. Considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation. **Top Gainers in Pre-market US Stocks** The LGL Group, Inc. is up 218.18% in pre-market trading, with no significant news recently. Trading is active, and capital flows are evident. Considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation. Freecast is up 205.15% in pre-market trading. Based on recent key news: 1. On June 12, FreeCast announced an expanded partnership with DIRECTV, driving a significant increase in stock price. This partnership integrates FreeCast's live TV and subscription management into a unified platform, attracting market attention and leading to a 100.93% increase in stock price. Source: Benzinga 2. Recently, FreeCast emphasized the advantages of its PaaS technology stack, combining live TV, FAST channels, advertising, and user management tools, which enhanced market confidence. This move further propelled positive stock performance. Source: Benzinga 3. On June 12, FreeCast's stock price activity showed significant growth, reflecting investor recognition of its platform integration capabilities. The stock price rose to $1.30 on that day. Source: Benzinga The market's increasing demand for streaming services has driven the stock price up. Paranovus ENT Tech is up 172.69% in pre-market trading. Based on recent key news: 1. On June 15, Paranovus Entertainment Technology Ltd. announced a significant breakthrough in its latest entertainment technology. This news triggered a strong market reaction, driving a substantial increase in stock price. 2. On June 15, the company released detailed information through ACCESS Newswire, further enhancing investor confidence, leading to continued stock price increases On June 15th, the market's expectations for the company's future growth potential significantly increased, leading investors to buy in and driving the stock price up. The entertainment technology industry has performed strongly recently, boosting investor confidence ### Related Stocks - [AKAN.US](https://longbridge.com/en/quote/AKAN.US.md) - [SONM.US](https://longbridge.com/en/quote/SONM.US.md) - [LGL.RT.US](https://longbridge.com/en/quote/LGL.RT.US.md) - [CAST.US](https://longbridge.com/en/quote/CAST.US.md) - [PAVS.US](https://longbridge.com/en/quote/PAVS.US.md) ## Related News & Research - [Another tough quarter for Fiserv may lead to product changes](https://longbridge.com/en/news/295271718.md) - [DNA: Q2 2026 revenue dropped 48% year-over-year, with major autonomous lab contracts secured](https://longbridge.com/en/news/295007946.md) - [Lucid Diagnostics Secures Commercial Coverage Policy Spanning Multiple Health Plans for its EsoGuard® Esophageal DNA Test | LUCD Stock News](https://longbridge.com/en/news/294970708.md) - [Lucid Diagnostics wins Concert coverage policy for EsoGuard esophageal DNA test across client health plans](https://longbridge.com/en/news/294970219.md) - [DNA: Revenue fell sharply but cash burn improved; autonomous labs and CRO services drive future growth](https://longbridge.com/en/news/295029402.md)